Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
Immunotherapy for Lymphoma
Recruiting1 awardPhase 2
Seattle, Washington
This trial is testing a combination of two immunotherapy drugs to treat patients with either follicular lymphoma or diffuse large B cell lymphoma that has returned or doesn't respond to treatment. The immunotherapy drugs are pembrolizumab and either rituximab or obinutuzumab. Rituximab and obinutuzumab are monoclonal antibodies that bind to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. The drugs may help kill more cancer cells.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service